Dr. Emens on the Combination of Checkpoint Inhibitors and PARP Inhibitors in Ovarian Cancer

Leisha A. Emens, MD, PhD, professor of medicine, Hematology/Oncology, co-leader, Hillman Cancer Immunology and Immunotherapy Program, director, Translational Immunotherapy for the Women’s Cancer Research Center, University of Pittsburgh Medical Center, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.
Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,